OCUL
Ocular Therapeutix, Inc
$10.27
-0.06 (-0.58%)
At close · Jul 8
Market Cap
$2.31B
Shares
218,960,358
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.27
Open$10.22
Day$9.92–10.43
52W$6.23–16.44
Avg vol 30d2.9M
Short int26.7M · 12.2% float · 6.6d
Short vol46%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+12%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
40%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+26%
trailing
6-month return
−2%
trailing
YTD return
−15%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Distributing
7 of 271 funds reported for Jun 30 · net -242 sh shares
Insider flow
Distributing
Net -$360.4K over 90 days · 100% sells
Short interest
Rising
12.19% of float · ▲ +0.9% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
271 holders — near 3-yr high, broad support
Squeeze score
91
high risk · 0–100
Fundamentals
Revenue growth
+300%
Y/Y
EPS growth
−16%
Y/Y
Free cash flow
$-216.9M
Balance sheet
$737.1M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+12%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
40%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Distributing
7 of 271 funds reported for Jun 30 · net -242 sh shares
Insider flow
Distributing
Net -$360.4K over 90 days · 100% sells
Short interest
Rising
12.19% of float · ▲ +0.9% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
271 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $10 · 40%
52-wk high $16
vs 200-day avg -1%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash | $667M | Q1 FY2026 call | — |
| original SOLAR subject target | 555 | Q1 FY2026 call | — |
| subjects randomized in SOLAR | 631 | Q1 FY2026 call | — |
| Gross proceeds from September 2025 equity offering | 475M | September 2025 | — |
| Net proceeds from September 2025 equity offering | 445.6M | September 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OCUL
this stock
Ocular Therapeutix, Inc
|
$2.31B | -15.4% | +13.5% | — | 12.2% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +9.5% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +8.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OCUL | +4.6% | +25.9% | -1.5% | +4.6% | -15.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +4.8% | +25.0% | -9.0% | +4.8% | -24.7% |